

Attorney Docket No.: ABLE0032US.NP  
Inventors: Urbaniak et al.  
Serial No.: Not yet assigned  
Filing Date: Herewith  
Page 3

This listing of the claims will replace all prior versions and listings of claims in the application:

**Listing of the claims:**

Claim 1 (currently amended): A ~~pharmaceutical~~ composition for the prevention or management of a condition caused by exposure to an antithetical allele of a platelet by transfusion or during pregnancy by tolerisation, the composition comprising an immunologically effective platelet protein or a peptide fragment thereof formulated for delivery through non-invasive routes.

Claim 2 (currently amended): A ~~pharmaceutical~~ The composition according to claim 1 wherein the condition is fetomaternal alloimmune response thrombocytopenia (FMAIT), post-transfusion purpura or platelet refractoriness.

Claim 3 (currently amended): A ~~pharmaceutical~~ The composition according to ~~either claim 1 or 2~~ claim 1 wherein the platelet protein is a human platelet antigen (HPA).

Claim 4 (currently amended): A ~~pharmaceutical~~ The composition according to claim 3 wherein the HPA is selected from the group consisting of HPA-1a, HPA-1b, HPA-2a, HPA-2b, HPA-3a, HPA-3b, HPA-4a, HPA-4b, HPA-5a, HPA-5b, HPA-6a, HPA-6b, HPA-7a, HPA-7b, HPA-8a, HPA-8b, HPA-9a, HPA-9b, HPA-10a, HPA-10b, HPA-11a, and HPA-11b.

Claim 5 (currently amended): A ~~pharmaceutical~~ The composition according to claim 4 wherein the HPA has a genotype HPA-1a.

Attorney Docket No.: **ABLE0032US.NP**  
Inventors: **Urbaniak et al.**  
Serial No.: **Not yet assigned**  
Filing Date: **Herewith**  
Page 4

Claim 6 (currently amended): ~~A pharmaceutical~~ The composition according to claim 5 wherein the HPA-1a has sequence SEQ ID No:1, 2, 3, 4, 5, 6 or 7.

Claim 7 (currently amended): ~~A pharmaceutical~~ The composition according to ~~any preceding claim~~ claim 1 wherein the ~~composition~~ immunologically effective platelet protein or a peptide fragment thereof is formulated for delivery through mucosal tissue.

Claims 8-10 (canceled)

Claim 11 (new): A method for the prevention or management of a condition caused by exposure to an antithetical allele of a platelet by transfusion or during pregnancy by tolerisation, the method comprising administering to a patient an immunologically effective platelet protein or a peptide fragment thereof.

Claim 12 (new): The method according to claim 11 wherein the condition is fetomaternal alloimmune response thrombocytopenia (FMAIT), post-transfusion purpura or platelet refractoriness.

Claim 13 (new): The method according to claim 11 wherein the platelet protein is a human platelet antigen (HPA).

Claim 14 (new): The method according to claim 13 wherein the HPA is selected from the group consisting of HPA-1a, HPA-1b, HPA-2a, HPA-2b, HPA-3a, HPA-3b, HPA-4a, HPA-4b, HPA-5a, HPA-5b, HPA-6a, HPA-6b, HPA-7a, HPA-7b, HPA-8a, HPA-8b, HPA-9a, HPA-9b, HPA-10a,

Attorney Docket No.: **ABLE0032US.NP**  
Inventors: **Urbaniak et al.**  
Serial No.: **Not yet assigned**  
Filing Date: **Herewith**  
Page 5

HPA-10b, HPA-11a and HPA-11b.

Claim 15 (new): The method according to claim 14 wherein the HPA has a genotype HPA-1a.

Claim 16 (new): The method according to claim 15 wherein the HPA-1a has sequence SEQ ID No:1, 2, 3, 4, 5, 6 or 7.

Claim 17 (new): The method according to claim 11 wherein the immunologically effective platelet protein or the peptide fragment thereof is formulated for delivery through mucosal tissue.